Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Teresa Giovanna María Aguilar-Macedo has a total of 9 co-authors. Here are the top co-authors by number of shared publications:

  • Alejandra Palacios-Ramírez

    Servicio de Ginecología Oncológica, Unidad Médica de Alta Especialidad, Hospital de Ginecología y Obstetricia, Centro Médico Nacional de Occidente (CMNO), Instituto Mexicano del Seguro Social (IMSS), Guadalajara 44329, Jalisco, Mexico

    1 shared publication
  • Clara Ibet Juárez-Vázquez

    Dirección Académica Aparatos y Sistemas I, Facultad de Medicina, Decanato Ciencias de la Salud, Universidad Autónoma de Guadalajara (UAG), Zapopan 45129, Mexico

    1 shared publication
  • César de Jesús Tovar-Jácome

    División de Medicina Molecular, Centro de Investigación Biomédica de Occidente (CIBO), Instituto Mexicano del Seguro Social (IMSS), Sierra Mojada 800, Col. Independencia, Guadalajara 44340, Mexico

    1 shared publication
  • Efraín Salas-González

    Servicio de Oncología Médica, Unidad Médica de Alta Especialidad, Hospital de Ginecología y Obstetricia, Centro Médico Nacional de Occidente (CMNO), Instituto Mexicano del Seguro Social (IMSS), Guadalajara 44340, Jalisco, Mexico

    1 shared publication
  • José Elías García-Ortiz

    División de Genética, Centro de Investigación Biomédica de Occidente (CIBO), Centro Médico Nacional de Occidente (CMNO), Instituto Mexicano del Seguro Social (IMSS), Guadalajara 44340, Jalisco, Mexico

    1 shared publication
  • Martha Patricia Gallegos-Arreola

    División de Genética, Centro de Investigación Biomédica de Occidente (CIBO), Centro Médico Nacional de Occidente (CMNO), Instituto Mexicano del Seguro Social (IMSS), Guadalajara 44340, Jalisco, Mexico

    1 shared publication

Latest Publications

  • Open Access

    Genetic Variants in BIRC5 (rs8073069, rs17878467, and rs9904341) Are Associated with Susceptibility in Mexican Patients with Breast Cancer: Clinical Associations and Their Analysis In Silico

    by María Renee Jiménez-López, César de Jesús Tovar-Jácome, Alejandra Palacios-Ramírez, Martha Patricia Gallegos-Arreola, Teresa Giovanna María Aguilar-Macedo, Rubria Alicia González-Sánchez, Efraín Salas-González, José Elías García-Ortiz, Clara Ibet Juárez-Vázquez, Mónica Alejandra Rosales-Reynoso

    Background/Objectives: Breast cancer (BC) is a multifactorial disease, with genetic alterations in cell proliferation and migration pathways being significant risk factors. This study examines the association between three variants in the BIRC5 gene (rs8073069, rs17878467, and rs9904341) and breast cancer (BC) susceptibility. Methods: Peripheral blood DNA samples were collected from 423 women (221 BC patients and 202 healthy controls). Genotyping was performed by polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) methodology. Associations were calculated using odds ratios (OR), with p-values adjusted by the Bonferroni test (significance at p ≤ 0.016). In silico analyses were conducted to predict the functional impact of the analyzed variants. Results: Patients carrying the C/C genotype for the rs8073069 variant showed increased susceptibility to BC with early TNM (tumor-node-metastasis classification) stage and Luminal A subtype (OR > 2.00; p ≤ 0.004). For the rs17878467 variant, patients with the C/T or T/T genotype exhibited a higher susceptibility to developing breast cancer (BC), particularly at early TNM stages or with a histological lobular type (OR > 2.00; p ≤ 0.012). Regarding the rs9904341 variant, patients with the G/C or C/C genotype had a higher susceptibility to breast cancer. Notably, G/C genotype carriers with Luminal A and B subtypes, and C/C genotype carriers who had TNM stages II and III, and Luminal A, Luminal B, and HER2 subtypes demonstrated increased risk (OR > 2.00; p ≤ 0.009). The C-T-C haplotype (rs8073069–rs17878467–rs9904341) was significantly associated with BC (OR = 4.20; 95% CI = 2.38–7.41; p ≤ 0.001). In silico analysis using CADD indicated a low probability of deleterious effects. Conclusions: The results suggest that the rs8073069, rs17878467, and rs9904341 variants in BIRC5 have a significant influence on breast cancer susceptibility.